| 1 | The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometrics | 3.1 | 12 | Citations (PDF) |
| 2 | Genetic interaction analysis of
Candida glabrata
transcription factors
CST6
and
UPC2A
in the regulation of respiration and fluconazole susceptibility | 4.1 | 1 | Citations (PDF) |
| 3 | A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response | 12.5 | 5 | Citations (PDF) |
| 4 | Candida albicans
biofilm extracellular vesicles deliver candidalysin to epithelial cell membranes and induce host cell responses | 2.7 | 6 | Citations (PDF) |
| 5 | Activity of rezafungin against Candida auris | 3.1 | 2 | Citations (PDF) |
| 6 | Nanoemulsion-based nanoplatform as a new PEITC nano - delivery system to pancreatic cancer cells | 3.2 | 1 | Citations (PDF) |
| 7 | Adhesin Als4112 promotes Candida auris skin colonization through interactions with keratinocytes and extracellular matrix proteins | 13.7 | 6 | Citations (PDF) |
| 8 | Liposomal formulation of a new antifungal hybrid compound provides protection against
Candida auris
in the
ex vivo
skin colonization model | 4.1 | 17 | Citations (PDF) |
| 9 | Candida albicans extracellular vesicles trigger type I IFN signalling via cGAS and STING | 16.0 | 57 | Citations (PDF) |
| 10 | Modeling Invasive Aspergillosis Risk for the Application of Prophylaxis Strategies | 0.8 | 16 | Citations (PDF) |
| 11 | In vivo
pharmacodynamic characterization of a next-generation polyene, SF001, in the invasive pulmonary aspergillosis mouse model | 4.1 | 9 | Citations (PDF) |
| 12 | Secretion of the fungal toxin candidalysin is dependent on conserved precursor peptide sequences | 16.0 | 15 | Citations (PDF) |
| 13 | Outcomes by
Candida
spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis | 4.1 | 21 | Citations (PDF) |
| 14 | Biofilm-associated metabolism via ERG251 in Candida albicans | 4.4 | 12 | Citations (PDF) |
| 15 | Piperacillin/Tazobactam Susceptibility Test Interpretive Criteria for Enterobacterales: Recommendations From the United States Committee on Antimicrobial Susceptibility Testing | 5.2 | 3 | Citations (PDF) |
| 16 | Metabolic reprogramming during Candida albicans planktonic-biofilm transition is modulated by the transcription factors Zcf15 and Zcf26 | 5.0 | 7 | Citations (PDF) |
| 17 | Systematic analysis of the
Candida albicans
kinome reveals environmentally contingent protein kinase-mediated regulation of filamentation and biofilm formation
in vitro
and
in vivo | 4.4 | 7 | Citations (PDF) |
| 18 | In vivo
pharmacodynamic evaluation of the novel nystatin derivative BSG005 in the invasive candidiasis and invasive pulmonary aspergillosis mouse models | 4.1 | 3 | Citations (PDF) |
| 19 | Reinforcement amid genetic diversity in the Candida albicans biofilm regulatory network | 4.4 | 30 | Citations (PDF) |
| 20 | Under-oil open microfluidic systems for rapid phenotypic antimicrobial susceptibility testing | 5.1 | 19 | Citations (PDF) |
| 21 | Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric Approaches | 4.1 | 11 | Citations (PDF) |
| 22 | Development of an in vitro pharmacokinetic/pharmacodynamic model in the presence of serum for studying micafungin activity against Candida albicans: a need for revision of CLSI susceptibility breakpoints | 3.1 | 2 | Citations (PDF) |
| 23 | Novel Keto-Alkyl-Pyridinium Antifungal Molecules Active in Models of
In Vivo
Candida albicans Vascular Catheter Infection and
Ex Vivo
Candida auris Skin Colonization | 4.1 | 8 | Citations (PDF) |
| 24 | Identification of triazenyl indoles as inhibitors of fungal fatty acid biosynthesis with broad-spectrum activity | 6.2 | 23 | Citations (PDF) |
| 25 | Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists | 2.8 | 68 | Citations (PDF) |
| 26 | The
Candida albicans
reference strain SC5314 contains a rare, dominant allele of the transcription factor Rob1 that modulates filamentation, biofilm formation, and oral commensalism | 4.4 | 30 | Citations (PDF) |
| 27 | A
Candida auris
–specific adhesin, Scf1
,
governs surface association, colonization, and virulence | 36.2 | 90 | Citations (PDF) |
| 28 | Role of the extracellular matrix in Candida biofilm antifungal resistance | 10.6 | 23 | Citations (PDF) |
| 29 | Tuning sterol extraction kinetics yields a renal-sparing polyene antifungal | 37.9 | 82 | Citations (PDF) |
| 30 | Genome Mining and Metabolomics Unveil Pseudonochelin: A Siderophore Containing 5-Aminosalicylate from a Marine-Derived Pseudonocardia sp. Bacterium | 4.8 | 13 | Citations (PDF) |
| 31 | Targeting fungal membrane homeostasis with imidazopyrazoindoles impairs azole resistance and biofilm formation | 13.7 | 41 | Citations (PDF) |
| 32 | Validated Preclinical Mouse Model for Therapeutic Testing against Multidrug-Resistant Pseudomonas aeruginosa Strains | 3.6 | 8 | Citations (PDF) |
| 33 | A common vesicle proteome drives fungal biofilm development | 7.5 | 48 | Citations (PDF) |
| 34 | Structural and functional analysis of EntV reveals a 12 amino acid fragment protective against fungal infections | 13.7 | 25 | Citations (PDF) |
| 35 | Novel approaches for the treatment of methicillin-resistant Staphylococcus aureus: Using nanoparticles to overcome multidrug resistance | 6.6 | 55 | Citations (PDF) |
| 36 | The protein kinase Ire1 impacts pathogenicity of
Candida albicans
by regulating homeostatic adaptation to endoplasmic reticulum stress | 1.6 | 29 | Citations (PDF) |
| 37 | Chemical Exchanges between Multilateral Symbionts | 4.8 | 21 | Citations (PDF) |
| 38 | Formation and characterization of biofilms formed by salt-tolerant yeast strains in seawater-based growth medium | 4.0 | 10 | Citations (PDF) |
| 39 | Turbinmicin inhibits Candida biofilm growth by disrupting fungal vesicle–mediated trafficking | 10.6 | 53 | Citations (PDF) |
| 40 | Model‐Informed Drug Development for Anti‐Infectives: State of the Art and Future | 4.7 | 64 | Citations (PDF) |
| 41 | The Role of New Posaconazole Formulations in the Treatment of Candida albicans Infections: Data from an
In Vitro
Pharmacokinetic-Pharmacodynamic Model | 4.1 | 7 | Citations (PDF) |
| 42 | Managing uncertainty in antifungal dosing: antibiograms, therapeutic drug monitoring and drug-drug interactions | 3.4 | 10 | Citations (PDF) |
| 43 | Implementation of telehealth antimicrobial stewardship through partnership of an academic medical center and a community hospital | 1.0 | 12 | Citations (PDF) |
| 44 | Regulatory Level of Evidence and Practicality in Antifungal Use Decisions for Less Common Fungal Diseases | 5.2 | 2 | Citations (PDF) |
| 45 | Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology | 16.5 | 227 | Citations (PDF) |
| 46 | Specialized Metabolites Reveal Evolutionary History and Geographic Dispersion of a Multilateral Symbiosis | 9.2 | 34 | Citations (PDF) |
| 47 | A small molecule produced by Lactobacillus species blocks Candida albicans filamentation by inhibiting a DYRK1-family kinase | 13.7 | 99 | Citations (PDF) |
| 48 | Coordination of fungal biofilm development by extracellular vesicle cargo | 13.7 | 99 | Citations (PDF) |
| 49 | Folate Functionalized Lipid Nanoparticles for Targeted Therapy of Methicillin-Resistant Staphylococcus aureus | 4.9 | 18 | Citations (PDF) |
| 50 | Continuous flow synthesis and antimicrobial evaluation of NHC* silver carboxylate derivatives of SBC3 in vitro and in vivo | 2.6 | 11 | Citations (PDF) |
| 51 | A Label-Free Cellular Proteomics Approach to Decipher the Antifungal Action of DiMIQ, a Potent Indolo[2,3-b]Quinoline Agent, against Candida albicans Biofilms | 4.4 | 6 | Citations (PDF) |
| 52 | Preventing Pseudomonas aeruginosa Biofilms on Indwelling Catheters by Surface-Bound Enzymes | 4.7 | 31 | Citations (PDF) |
| 53 | Candidemia in the Growing Opioid Epidemic: A Distinct and Emerging Entity | 5.2 | 2 | Citations (PDF) |
| 54 | Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium | 5.2 | 2,343 | Citations (PDF) |
| 55 | Biomineral armor in leaf-cutter ants | 13.7 | 53 | Citations (PDF) |
| 56 | Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium | 3.8 | 142 | Citations (PDF) |
| 57 | Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube | 3.1 | 17 | Citations (PDF) |
| 58 | Pharmacodynamic Evaluation of MRX-8, a Novel Polymyxin, in the Neutropenic Mouse Thigh and Lung Infection Models against Gram-Negative Pathogens | 4.1 | 41 | Citations (PDF) |
| 59 | An oxindole efflux inhibitor potentiates azoles and impairs virulence in the fungal pathogen Candida auris | 13.7 | 67 | Citations (PDF) |
| 60 | Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated
In Vitro
Pharmacokinetic/Pharmacodynamic Model | 4.1 | 5 | Citations (PDF) |
| 61 | Pyridine-2,6-Dithiocarboxylic Acid and Its Metal Complexes: New Inhibitors of New Delhi Metallo -Lactamase-1 | 5.2 | 8 | Citations (PDF) |
| 62 | Old In Vitro Antimicrobial Breakpoints Are Misleading Stewardship Efforts, Delaying Adoption of Innovative Therapies, and Harming Patients | 0.8 | 14 | Citations (PDF) |
| 63 | Contributions of the Biofilm Matrix to Candida Pathogenesis | 3.5 | 111 | Citations (PDF) |
| 64 | A targeted fungal prophylaxis protocol with static dosed fluconazole significantly reduces invasive fungal infection after liver transplantation | 2.2 | 13 | Citations (PDF) |
| 65 | The Candida albicans biofilm gene circuit modulated at the chromatin level by a recent molecular histone innovation | 5.0 | 29 | Citations (PDF) |
| 66 | Characterization of an Uncinocarpus reesii-expressed recombinant tube precipitin antigen of Coccidioides posadasii for serodiagnosis | 2.3 | 6 | Citations (PDF) |
| 67 | MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis | 3.1 | 82 | Citations (PDF) |
| 68 | Pyonitrins A–D: Chimeric Natural Products Produced by <i>Pseudomonas protegens</i> | 15.0 | 38 | Citations (PDF) |
| 69 | <i>In vivo</i>pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model | 3.1 | 29 | Citations (PDF) |
| 70 | <i>In Vivo</i>
Pharmacodynamic Target Determination for Delafloxacin against Klebsiella pneumoniae and Pseudomonas aeruginosa in the Neutropenic Murine Pneumonia Model | 4.1 | 11 | Citations (PDF) |
| 71 | Exploiting the vulnerable active site of a copper-only superoxide dismutase to disrupt fungal pathogenesis | 2.2 | 22 | Citations (PDF) |
| 72 | APX001 Pharmacokinetic/Pharmacodynamic Target Determination against
<i>Aspergillus fumigatus</i>
in an
<i>In Vivo</i>
Model of Invasive Pulmonary Aspergillosis | 4.1 | 45 | Citations (PDF) |
| 73 | The antimicrobial potential of Streptomyces from insect microbiomes | 13.7 | 302 | Citations (PDF) |
| 74 | Bacterial Infections in the Stem Cell Transplant Recipient and Hematologic Malignancy Patient | 3.2 | 24 | Citations (PDF) |
| 75 | Small-Molecule Morphogenesis Modulators Enhance the Ability of 14-Helical β-Peptides To Prevent Candida albicans Biofilm Formation | 4.1 | 8 | Citations (PDF) |
| 76 | WCK 5222 (Cefepime-Zidebactam) Pharmacodynamic Target Analysis against Metallo-β-Lactamase-Producing
<i>Enterobacteriaceae</i>
in the Neutropenic Mouse Pneumonia Model | 4.1 | 29 | Citations (PDF) |
| 77 | Variability and exposure–response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases | 3.1 | 67 | Citations (PDF) |
| 78 | Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae | 4.1 | 16 | Citations (PDF) |
| 79 | Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials | 4.1 | 23 | Citations (PDF) |
| 80 | How Clean Is the Linen at My Hospital? The Mucorales on Unclean Linen Discovery Study of Large United States Transplant and Cancer Centers | 5.2 | 41 | Citations (PDF) |
| 81 | Has the Optimal Therapy for Invasive Candidiasis Now Been Defined? | 5.2 | 6 | Citations (PDF) |
| 82 | Bacterial-derived exopolysaccharides enhance antifungal drug tolerance in a cross-kingdom oral biofilm | 9.1 | 136 | Citations (PDF) |
| 83 | Pharmacokinetics–pharmacodynamics, computer decision support technologies, and antimicrobial stewardship: the compass and rudder | 1.6 | 8 | Citations (PDF) |
| 84 | Conservation and Divergence in the
Candida
Species Biofilm Matrix Mannan-Glucan Complex Structure, Function, and Genetic Control | 4.4 | 69 | Citations (PDF) |
| 85 | In Vivo
Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model | 4.1 | 61 | Citations (PDF) |
| 86 | We can do better: a fresh look at echinocandin dosing | 3.1 | 42 | Citations (PDF) |
| 87 | 1389. Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model Against S. aureus (SA) and S. pneumoniae (SPN) | 0.8 | 1 | Citations (PDF) |
| 88 | 406. Achievement of Clinical Isavuconazole (ISA) Serum and Plasma Drug Concentrations in Two Patients With Isavuconazonium Capsules Administered via Nasogastric Feeding Tube (NGT) | 0.8 | 0 | Citations (PDF) |
| 89 | Candida–streptococcal interactions in biofilm-associated oral diseases | 4.4 | 131 | Citations (PDF) |
| 90 | Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms | 3.0 | 112 | Citations (PDF) |
| 91 | <i>In Vivo</i>
Pharmacodynamic Characterization of a Novel Odilorhabdin Antibiotic, NOSO-502, against Escherichia coli and Klebsiella pneumoniae in a Murine Thigh Infection Model | 4.1 | 14 | Citations (PDF) |
| 92 | Topical Delivery of Ebselen Encapsulated in Biopolymeric Nanocapsules: Drug Repurposing Enhanced Antifungal Activity | 3.0 | 40 | Citations (PDF) |
| 93 | Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design | 4.1 | 61 | Citations (PDF) |
| 94 | In Vivo
Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model | 4.1 | 48 | Citations (PDF) |
| 95 | Antifungal Efficacy of an Intravenous Formulation Containing Monomeric Amphotericin B, 5-Fluorocytosine, and Saline for Sodium Supplementation | 3.7 | 14 | Citations (PDF) |
| 96 | In Vivo
Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa | 4.1 | 94 | Citations (PDF) |
| 97 | In Vivo
Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model | 4.1 | 40 | Citations (PDF) |
| 98 | Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus | 4.1 | 25 | Citations (PDF) |
| 99 | Pharmacodynamic Optimization for the Treatment of Invasive Candida auris Infection | 0.8 | 1 | Citations (PDF) |
| 100 | In vivo infection models in the pre-clinical pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents | 3.8 | 49 | Citations (PDF) |
| 101 | Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters | 4.1 | 34 | Citations (PDF) |
| 102 | Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi | 4.1 | 105 | Citations (PDF) |
| 103 | Distinct roles of the 7-transmembrane receptor protein Rta3 in regulating the asymmetric distribution of phosphatidylcholine across the plasma membrane and biofilm formation inCandida albicans | 1.6 | 21 | Citations (PDF) |
| 104 | The Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus | 3.8 | 14 | Citations (PDF) |
| 105 | Minocycline Enhances the Antimicrobial Capacity of Unpolarized Macrophages Against Acinetobacter baumannii While Inducing an Anti-inflammatory Profile | 0.8 | 1 | Citations (PDF) |
| 106 | Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats | 4.1 | 71 | Citations (PDF) |
| 107 | Breaking New Ground: An Evaluation of Susceptibility Breakpoints for Echinocandins against Candida Species | 0.8 | 0 | Citations (PDF) |
| 108 | Candida albicans FRE8 encodes a member of the NADPH oxidase family that produces a burst of ROS during fungal morphogenesis | 4.4 | 70 | Citations (PDF) |
| 109 | Traditional PK-PD Indices for Efficacy – Can We Do Better? | 0.8 | 4 | Citations (PDF) |
| 110 | Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection | 4.1 | 78 | Citations (PDF) |
| 111 | Bypass of Candida albicans Filamentation/Biofilm Regulators through Diminished Expression of Protein Kinase Cak1 | 3.2 | 46 | Citations (PDF) |
| 112 | Comparative In Vivo Pharmacokinetics/Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh Infection Model Against Staphylococcus aureus | 0.8 | 0 | Citations (PDF) |
| 113 | Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses for Delafloxacin to Provide Dose Selection Support for the Treatment of Patients With Community-Acquired Bacterial Pneumonia (CABP) | 0.8 | 2 | Citations (PDF) |
| 114 | Pleiotropic effects of the vacuolar ABC transporter MLT1 of Candida albicans on cell function and virulence | 3.8 | 34 | Citations (PDF) |
| 115 | Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients | 4.1 | 51 | Citations (PDF) |
| 116 | Commensal Protection of Staphylococcus aureus against Antimicrobials by Candida albicans Biofilm Matrix | 4.4 | 258 | Citations (PDF) |
| 117 | Dual action antifungal small molecule modulates multidrug efflux and TOR signaling | 11.8 | 96 | Citations (PDF) |
| 118 | Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents | 2.6 | 92 | Citations (PDF) |
| 119 | The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: results of the Transplant‐Associated Infection Surveillance Network (TRANSNET) | 2.2 | 162 | Citations (PDF) |
| 120 | Global Identification of Biofilm-Specific Proteolysis in Candida albicans | 4.4 | 80 | Citations (PDF) |
| 121 | In Vivo
Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model | 4.1 | 47 | Citations (PDF) |
| 122 | Intraluminal Release of an Antifungal β-Peptide Enhances the Antifungal and Anti-Biofilm Activities of Multilayer-Coated Catheters in a Rat Model of Venous Catheter Infection | 5.3 | 33 | Citations (PDF) |
| 123 | Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America | 5.2 | 1,343 | Citations (PDF) |
| 124 | Antifungal Agents | 3.2 | 325 | Citations (PDF) |
| 125 | Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America | 5.2 | 3,405 | Citations (PDF) |
| 126 | Fungal Super Glue: The Biofilm Matrix and Its Composition, Assembly, and Functions | 4.4 | 116 | Citations (PDF) |
| 127 | Fungal Biofilms:
In Vivo
Models for Discovery of Anti-Biofilm Drugs | 3.6 | 55 | Citations (PDF) |
| 128 | Histoplasmosis Complicating Tumor Necrosis Factor–α Blocker Therapy: A Retrospective Analysis of 98 Cases | 5.2 | 134 | Citations (PDF) |
| 129 | Nontoxic antimicrobials that evade drug resistance | 11.8 | 83 | Citations (PDF) |
| 130 | An expanded regulatory network temporally controls
C
andida albicans
biofilm formation | 2.5 | 165 | Citations (PDF) |
| 131 | Pharmacodynamic Target Evaluation of a Novel Oral Glucan Synthase Inhibitor, SCY-078 (MK-3118), Using an
In Vivo
Murine Invasive Candidiasis Model | 4.1 | 90 | Citations (PDF) |
| 132 | In Vivo
Pharmacokinetics and Pharmacodynamics of the Lantibiotic NAI-107 in a Neutropenic Murine Thigh Infection Model | 4.1 | 35 | Citations (PDF) |
| 133 | Phaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET) | 0.6 | 99 | Citations (PDF) |
| 134 | Community participation in biofilm matrix assembly and function | 7.5 | 165 | Citations (PDF) |
| 135 | The synthesis of indolo[2,3-b]quinoline derivatives with a guanidine group: Highly selective cytotoxic agents | 5.3 | 49 | Citations (PDF) |
| 136 | In Vivo
Pharmacodynamic Evaluation of an FtsZ Inhibitor, TXA-709, and Its Active Metabolite, TXA-707, in a Murine Neutropenic Thigh Infection Model | 4.1 | 27 | Citations (PDF) |
| 137 | Application of 3D NMR for Structure Determination of Peptide Natural Products | 3.5 | 21 | Citations (PDF) |
| 138 | International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus | 19.3 | 295 | Citations (PDF) |
| 139 | Host Contributions to Construction of Three Device-Associated Candida albicans Biofilms | 2.7 | 70 | Citations (PDF) |
| 140 | Development of New Strategies for Echinocandins: Progress in Translational Research | 5.2 | 7 | Citations (PDF) |
| 141 | Antifungal Pharmacokinetics and Pharmacodynamics | 6.6 | 108 | Citations (PDF) |
| 142 | Comparative Phenotypic Analysis of the Major Fungal Pathogens Candida parapsilosis and Candida albicans | 4.4 | 118 | Citations (PDF) |
| 143 | A Histone Deacetylase Complex Mediates Biofilm Dispersal and Drug Resistance in Candida albicans | 4.4 | 80 | Citations (PDF) |
| 144 | Novel Entries in a Fungal Biofilm Matrix Encyclopedia | 4.4 | 273 | Citations (PDF) |
| 145 | Fungal Biofilms, Drug Resistance, and Recurrent Infection | 6.6 | 227 | Citations (PDF) |
| 146 | Daptomycin Dosing Based on Ideal Body Weight versus Actual Body Weight: Comparison of Clinical Outcomes | 4.1 | 23 | Citations (PDF) |
| 147 | Searching for new derivatives of neocryptolepine: Synthesis, antiproliferative, antimicrobial and antifungal activities | 5.3 | 36 | Citations (PDF) |
| 148 | Forazoline A: Marine‐Derived Polyketide with Antifungal In Vivo Efficacy | 14.4 | 114 | Citations (PDF) |
| 149 | Rat Indwelling Urinary Catheter Model of Candida albicans Biofilm Infection | 2.7 | 42 | Citations (PDF) |
| 150 | Failure of Clindamycin To Eradicate Infection with Beta-Hemolytic Streptococci Inducibly Resistant to Clindamycin in an Animal Model and in Human Infections | 4.1 | 17 | Citations (PDF) |
| 151 | Epidemiology and Outcomes of Invasive Candidiasis Due to Non-albicans Species of Candida in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004–2008 | 2.3 | 373 | Citations (PDF) |
| 152 | Synthesis and Antibacterial Activity of Doxycycline Neoglycosides | 3.6 | 19 | Citations (PDF) |
| 153 | Mechanisms of
Candida
Biofilm Drug Resistance | 2.0 | 382 | Citations (PDF) |
| 154 | The APSES transcription factor Efg1 is a global regulator that controls morphogenesis and biofilm formation in Candida parapsilosis | 2.5 | 53 | Citations (PDF) |
| 155 | Posaconazole Pharmacodynamic Target Determination against Wild-Type and
Cyp51
Mutant Isolates of Aspergillus fumigatus in an
In Vivo
Model of Invasive Pulmonary Aspergillosis | 4.1 | 71 | Citations (PDF) |
| 156 | Insights into fungal pathogenesis from the iatrogenic epidemic of Exserohilum rostratum fungal meningitis | 2.1 | 17 | Citations (PDF) |
| 157 | Optimizing antifungal choice and administration | 2.1 | 84 | Citations (PDF) |
| 158 | Regulatory Role of Glycerol in Candida albicans Biofilm Formation | 4.4 | 91 | Citations (PDF) |
| 159 | Isavuconazole Pharmacodynamic Target Determination for Candida Species in an
In Vivo
Murine Disseminated Candidiasis Model | 4.1 | 59 | Citations (PDF) |
| 160 | Inoculum Effects of Ceftobiprole, Daptomycin, Linezolid, and Vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at Inocula of 105and 107CFU Injected into Opposite Thighs of Neutropenic Mice | 4.1 | 50 | Citations (PDF) |
| 161 | Impact ofIn VivoTriazole and Echinocandin Combination Therapy for Invasive Pulmonary Aspergillosis: Enhanced Efficacy againstCyp51Mutant Isolates | 4.1 | 32 | Citations (PDF) |
| 162 | Reply to Oude Lashof and Vogelaers | 5.2 | 1 | Citations (PDF) |
| 163 | Isavuconazole (BAL4815) Pharmacodynamic Target Determination in an
In Vivo
Murine Model of Invasive Pulmonary Aspergillosis against Wild-Type and
cyp51
Mutant Isolates of Aspergillus fumigatus | 4.1 | 83 | Citations (PDF) |
| 164 | Preparation of Candida albicans Biofilms for Transmission Electron Microscopy | 0.4 | 4 | Citations (PDF) |
| 165 | Preparation of Candida albicans Biofilms Using an in vivo Rat Central Venous Catheter Model | 0.4 | 3 | Citations (PDF) |
| 166 | A Candida Biofilm-Induced Pathway for Matrix Glucan Delivery: Implications for Drug Resistance | 4.4 | 276 | Citations (PDF) |
| 167 | Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials | 5.2 | 744 | Citations (PDF) |
| 168 | Optimizing Echinocandin Dosing and Susceptibility Breakpoint Determination via
In Vivo
Pharmacodynamic Evaluation against Candida glabrata with and without
fks
Mutations | 4.1 | 41 | Citations (PDF) |
| 169 | Comparative Pharmacodynamics of the New Oxazolidinone Tedizolid Phosphate and Linezolid in a Neutropenic Murine Staphylococcus aureus Pneumonia Model | 4.1 | 53 | Citations (PDF) |
| 170 | A Recently Evolved Transcriptional Network Controls Biofilm Development in Candida albicans | 33.7 | 691 | Citations (PDF) |
| 171 | Comparative analysis ofCandidabiofilm quantitation assays | 0.6 | 72 | Citations (PDF) |
| 172 | Identification and Characterization of Antifungal Compounds Using a Saccharomyces cerevisiae Reporter Bioassay | 2.3 | 33 | Citations (PDF) |
| 173 | Protein Binding: Do We Ever Learn? | 4.1 | 240 | Citations (PDF) |
| 174 | Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting | 2.0 | 54 | Citations (PDF) |
| 175 | Optimizing a Candida Biofilm Microtiter Plate Model for Measurement of Antifungal Susceptibility by Tetrazolium Salt Assay | 4.0 | 141 | Citations (PDF) |
| 176 | Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria | 1.6 | 126 | Citations (PDF) |
| 177 | Conserved and Divergent Roles of Bcr1 and CFEM Proteins in Candida parapsilosis and Candida albicans | 2.3 | 87 | Citations (PDF) |
| 178 | Interface of Candida albicans Biofilm Matrix-Associated Drug Resistance and Cell Wall Integrity Regulation | 2.7 | 153 | Citations (PDF) |
| 179 | Antifungal PK/PD Considerations in Fungal Pulmonary Infections | 2.3 | 22 | Citations (PDF) |
| 180 | Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia | 4.1 | 111 | Citations (PDF) |
| 181 | Multilaboratory Testing of Two-Drug Combinations of Antifungals againstCandida albicans,Candida glabrata, andCandida parapsilosis | 4.1 | 47 | Citations (PDF) |
| 182 | Hsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms | 4.4 | 257 | Citations (PDF) |
| 183 | Calcineurin Controls Drug Tolerance, Hyphal Growth, and Virulence in Candida dubliniensis | 2.7 | 108 | Citations (PDF) |
| 184 | Comparison of In Vitro Susceptibility Characteristics of
Candida
Species from Cases of Invasive Candidiasis in Solid Organ and Stem Cell Transplant Recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006 | 4.0 | 59 | Citations (PDF) |
| 185 | The Role of Second-Generation Antifungal Triazoles for Treatment of the Endemic Mycoses | 2.6 | 7 | Citations (PDF) |
| 186 | Role of Fks1p and Matrix Glucan in
Candida albicans
Biofilm Resistance to an Echinocandin, Pyrimidine, and Polyene | 4.1 | 209 | Citations (PDF) |
| 187 | Factors Associated with Mortality in Transplant Patients with Invasive Aspergillosis | 5.2 | 296 | Citations (PDF) |
| 188 | Genetic Basis ofCandidaBiofilm Resistance Due to Drug‐Sequestering Matrix Glucan | 3.8 | 243 | Citations (PDF) |
| 189 | Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001–2006: Overview of the Transplant‐Associated Infection Surveillance Network (TRANSNET) Database | 5.2 | 1,325 | Citations (PDF) |
| 190 | Development and Validation of an
In Vivo Candida albicans
Biofilm Denture Model | 2.7 | 150 | Citations (PDF) |
| 191 | Invasive Fungal Infections among Organ Transplant Recipients: Results of the Transplant‐Associated Infection Surveillance Network (TRANSNET) | 5.2 | 1,450 | Citations (PDF) |
| 192 | Biofilm Matrix Regulation by Candida albicans Zap1 | 5.0 | 315 | Citations (PDF) |
| 193 | Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications | 4.1 | 468 | Citations (PDF) |
| 194 | Voriconazole Use for Endemic Fungal Infections | 4.1 | 137 | Citations (PDF) |
| 195 | Time Course Global Gene Expression Analysis of an In Vivo Candida Biofilm | 3.8 | 166 | Citations (PDF) |
| 196 | Guías de práctica clínica para el manejo de la candidiasis: actualización del 2009, de la Infectious Diseases Society of America | 5.2 | 8 | Citations (PDF) |
| 197 | Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America | 5.2 | 2,727 | Citations (PDF) |
| 198 | Pharmacokinetic–pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients | 1.6 | 51 | Citations (PDF) |
| 199 | Combination Antifungal Therapy Involving Amphotericin B, Rapamycin and 5-Fluorocytosine Using PEG-Phospholipid Micelles | 3.7 | 26 | Citations (PDF) |
| 200 | Pharmacodynamics of antifungal drugs: A strategy to optimize efficacy | 3.1 | 2 | Citations (PDF) |
| 201 | Review of techniques for diagnosis of catheter-related Candida biofilm infections | 3.1 | 4 | Citations (PDF) |
| 202 | Complementary Adhesin Function in C. albicans Biofilm Formation | 3.6 | 329 | Citations (PDF) |
| 203 | Rationale for Reading Fluconazole MICs at 24 Hours Rather than 48 Hours When Testing
Candida
spp. by the CLSI M27-A2 Standard Method | 4.1 | 43 | Citations (PDF) |
| 204 | Synergistic Effect of Calcineurin Inhibitors and Fluconazole against
Candida albicans
Biofilms | 4.1 | 224 | Citations (PDF) |
| 205 | Association of Fluconazole Pharmacodynamics with Mortality in Patients with Candidemia | 4.1 | 149 | Citations (PDF) |
| 206 | Activities of Clindamycin, Daptomycin, Doxycycline, Linezolid, Trimethoprim-Sulfamethoxazole, and Vancomycin against Community-Associated Methicillin-Resistant
Staphylococcus aureus
with Inducible Clindamycin Resistance in Murine Thigh Infection and In Vitro Pharmacodynamic Models | 4.1 | 96 | Citations (PDF) |
| 207 | Reduced Biocide Susceptibility in
Candida albicans
Biofilms | 4.1 | 65 | Citations (PDF) |
| 208 | In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin | 4.1 | 113 | Citations (PDF) |
| 209 | CNS pharmacokinetics of antifungal agents | 2.7 | 107 | Citations (PDF) |
| 210 | β‐1,3 Glucan as a Test for Central Venous Catheter Biofilm Infection | 3.8 | 89 | Citations (PDF) |
| 211 | Eap1p, an Adhesin That Mediates Candida albicans Biofilm Formation In Vitro and In Vivo | 2.7 | 140 | Citations (PDF) |
| 212 | Clinical practice guideline: Adult sinusitis | 2.3 | 802 | Citations (PDF) |
| 213 | Putative Role of β-1,3 Glucans in Candida albicans Biofilm Resistance | 4.1 | 399 | Citations (PDF) |
| 214 | CNS pharmacokinetics of antifungal agents | 2.7 | 52 | Citations (PDF) |
| 215 | Pharmacology of Systemic Antifungal Agents | 5.2 | 272 | Citations (PDF) |
| 216 | Pharmacokinetics and Pharmacodynamics of Antifungals | 3.2 | 97 | Citations (PDF) |
| 217 | Candida albicans biofilm development, modeling a host–pathogen interaction | 7.0 | 207 | Citations (PDF) |
| 218 | Alcohol Dehydrogenase Restricts the Ability of the Pathogen Candida albicans To Form a Biofilm on Catheter Surfaces through an Ethanol-Based Mechanism | 2.7 | 145 | Citations (PDF) |
| 219 | Clinical Research in the Lay Press: Irresponsible Journalism Raises a Huge Dose of Doubt | 5.2 | 3 | Citations (PDF) |
| 220 | Critical Role of Bcr1-Dependent Adhesins in C. albicans Biofilm Formation In Vitro and In Vivo | 4.4 | 476 | Citations (PDF) |
| 221 | Fungal pathogenesis: Bridging the gap between the bedside and the bench | 2.5 | 1 | Citations (PDF) |
| 222 | The Microbe-Host Interface in Respiratory Tract Infections Edited by Jan L. L. Kimpen and Octavio Ramilo Wymondham, UK: Horizon Bioscience, 2005. 323 pp., illustrated. $139.95 (cloth) | 5.2 | 0 | Citations (PDF) |
| 223 | In Vivo Pharmacodynamic Activity of Daptomycin | 4.1 | 373 | Citations (PDF) |
| 224 | Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections | 1.1 | 85 | Citations (PDF) |
| 225 | Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance | 19.3 | 18 | Citations (PDF) |
| 226 | Clinical utility of antifungal pharmacokinetics and pharmacodynamics | 3.4 | 42 | Citations (PDF) |
| 227 | Clinical pharmacodynamics of antifungals | 3.2 | 27 | Citations (PDF) |
| 228 | In Vivo Pharmacodynamics of Antifungal Drugs in Treatment of Candidiasis | 4.1 | 161 | Citations (PDF) |
| 229 | Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections | 3.4 | 43 | Citations (PDF) |
| 230 | Use of Pharmacodynamic Indices To Predict Efficacy of Combination Therapy In Vivo | 4.1 | 68 | Citations (PDF) |
| 231 | PHARMACOKINETICS AND PHARMACODYNAMICS OF OUTPATIENT INTRAVENOUS ANTIMICROBIAL THERAPY | 3.2 | 30 | Citations (PDF) |
| 232 | Pharmacodynamics of Fluoroquinolones in Experimental Models of Endocarditis | 5.2 | 58 | Citations (PDF) |
| 233 | Pharmacokinetics and pharmacodynamics of antibiotics in otitis media | 1.1 | 429 | Citations (PDF) |
| 234 | Pharmacokinetics and pharmacodynamics of antibiotics in otitis media* | 1.1 | 49 | Citations (PDF) |
| 235 | Evolution of the complex transcription network controlling biofilm formation in Candida species | 1.6 | 41 | Citations (PDF) |
| 236 | Transcriptional rewiring over evolutionary timescales changes quantitative and qualitative properties of gene expression | 1.6 | 66 | Citations (PDF) |
| 237 | Loss of CclA, required for histone 3 lysine 4 methylation, decreases growth but increases secondary metabolite production in
Aspergillus fumigatus | 0.0 | 72 | Citations (PDF) |
| 238 | Plasma Microbial Cell-free DNA Metagenomic Sequencing for Diagnosis of Invasive Fungal Diseases Among High-risk Outpatient and Inpatient Immunocompromised Hosts | 5.2 | 4 | Citations (PDF) |
| 239 | Ume6 protein complexes connect morphogenesis, adherence and hypoxic genes to shape Candida albicans biofilm architecture | 16.0 | 3 | Citations (PDF) |
| 240 | The antifungal mechanism of EntV-derived peptides is associated with a reduction in extracellular vesicle release | 4.4 | 0 | Citations (PDF) |
| 241 | Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and
<i>Pseudomonas aeruginosa</i> | 0.8 | 1 | Citations (PDF) |
| 242 | Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and
<i>Pseudomonas aeruginosa</i>
: Brief Summary | 0.8 | 0 | Citations (PDF) |
| 243 | Evaluation of an
in vivo
pulmonary aspergillosis model for triazole susceptibility breakpoint development | 4.1 | 0 | Citations (PDF) |
